Compare Torrent Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CIPLA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CIPLA TORRENT PHARMA/
CIPLA
 
P/E (TTM) x 36.5 34.2 106.7% View Chart
P/BV x 9.2 4.8 191.2% View Chart
Dividend Yield % 0.7 0.4 155.8%  

Financials

 TORRENT PHARMA   CIPLA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
CIPLA
Mar-20
TORRENT PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,964586 335.4%   
Low Rs1,245357 348.9%   
Sales per share (Unadj.) Rs453.4207.0 219.0%  
Earnings per share (Unadj.) Rs25.818.6 138.6%  
Cash flow per share (Unadj.) Rs62.333.2 187.8%  
Dividends per share (Unadj.) Rs17.004.00 425.0%  
Dividend yield (eoy) %1.10.8 124.8%  
Book value per share (Unadj.) Rs279.2195.5 142.8%  
Shares outstanding (eoy) m169.22806.35 21.0%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.52.3 155.5%   
Avg P/E ratio x62.225.3 245.6%  
P/CF ratio (eoy) x25.814.2 181.3%  
Price / Book Value ratio x5.72.4 238.5%  
Dividend payout %65.921.5 306.5%   
Avg Mkt Cap Rs m271,513379,912 71.5%   
No. of employees `00013.625.8 52.6%   
Total wages/salary Rs m14,03830,270 46.4%   
Avg. sales/employee Rs Th5,642.66,459.6 87.4%   
Avg. wages/employee Rs Th1,032.41,171.2 88.1%   
Avg. net profit/employee Rs Th320.9580.2 55.3%   
INCOME DATA
Net Sales Rs m76,728166,949 46.0%  
Other income Rs m5713,442 16.6%   
Total revenues Rs m77,299170,391 45.4%   
Gross profit Rs m19,83132,060 61.9%  
Depreciation Rs m6,17711,747 52.6%   
Interest Rs m5,0381,974 255.2%   
Profit before tax Rs m9,18721,782 42.2%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2546,312 19.9%   
Profit after tax Rs m4,36314,995 29.1%  
Gross profit margin %25.819.2 134.6%  
Effective tax rate %13.629.0 47.1%   
Net profit margin %5.79.0 63.3%  
BALANCE SHEET DATA
Current assets Rs m50,375117,038 43.0%   
Current liabilities Rs m51,65343,931 117.6%   
Net working cap to sales %-1.743.8 -3.8%  
Current ratio x1.02.7 36.6%  
Inventory Days Days9296 96.2%  
Debtors Days Days6885 80.3%  
Net fixed assets Rs m83,648107,424 77.9%   
Share capital Rs m8461,613 52.5%   
"Free" reserves Rs m46,397156,018 29.7%   
Net worth Rs m47,244157,630 30.0%   
Long term debt Rs m39,12923,693 165.2%   
Total assets Rs m141,209236,626 59.7%  
Interest coverage x2.812.0 23.5%   
Debt to equity ratio x0.80.2 551.0%  
Sales to assets ratio x0.50.7 77.0%   
Return on assets %6.77.2 92.8%  
Return on equity %9.29.5 97.1%  
Return on capital %12.312.8 96.1%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10356,036 39.4%   
Fx outflow Rs m5,5226,764 81.6%   
Net fx Rs m16,58149,272 33.7%   
CASH FLOW
From Operations Rs m17,98130,685 58.6%  
From Investments Rs m-2,4131,040 -231.9%  
From Financial Activity Rs m-13,145-29,488 44.6%  
Net Cashflow Rs m2,3802,340 101.7%  

Share Holding

Indian Promoters % 71.5 16.0 446.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.0 12.2 57.5%  
FIIs % 12.6 23.7 53.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.8 26.2 33.6%  
Shareholders   26,511 161,166 16.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 22, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS